Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study
Authors
Keywords
Sorafenib, Liver Resection, Hepatic Encephalopathy, Sorafenib Treatment, Sorafenib Therapy
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 20, Issue 11, Pages 3603-3609
Publisher
Springer Nature
Online
2013-05-29
DOI
10.1245/s10434-013-3029-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effects of sorafenib on liver regeneration in a model of partial hepatectomy
- (2012) Peter C. Kurniali et al. JOURNAL OF SURGICAL RESEARCH
- Evaluation of the mRECIST and a-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
- (2012) Tomokazu Kawaoka et al. ONCOLOGY
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection
- (2011) Sabine Irtan et al. LIVER INTERNATIONAL
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
- (2011) Romain Coriat et al. PLoS One
- Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma
- (2011) Nicolas Williet WORLD JOURNAL OF GASTROENTEROLOGY
- Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach
- (2010) F. Bathaix et al. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
- Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model
- (2010) Yu-Xiong Feng et al. HEPATOLOGY
- Effect of sorafenib on murine liver regeneration
- (2010) Caroline Hora et al. HEPATOLOGY
- Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice
- (2010) Masatoshi Kudo International Journal of Clinical Oncology
- Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma
- (2010) C. Lance Cowey et al. JOURNAL OF CLINICAL ONCOLOGY
- Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
- (2010) Masatoshi Kudo et al. ONCOLOGY
- Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report
- (2010) Sean Xiang Wang et al. Targeted Oncology
- Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab
- (2009) Béatrice Aussilhou et al. ANNALS OF SURGICAL ONCOLOGY
- Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
- (2009) Marius Horger et al. BMC CANCER
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
- (2008) Marc Mejias et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started